AbCellera Biologics Inc. (FRA:8QQ)

Market Cap	912.06M +7.3%
Revenue (ttm)	30.11M +7.2%
Net Income	-146.32M
EPS	-0.49
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,229
Open	3.212
Previous Close	3.428
Day's Range	3.212 - 3.212
52-Week Range	1.701 - 5.780
Beta	n/a
RSI	45.43
Earnings Date	Feb 24, 2026

About AbCellera Biologics

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 596
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8QQ

Financial Performance

In 2024, AbCellera Biologics's revenue was $28.83 million, a decrease of -24.17% compared to the previous year's $38.03 million. Losses were -$162.86 million, 11.2% more than in 2023.

Financial numbers in USD